argenx company profile

ARGX · Euronext Brussels · EUR

Compare argenx

Secondary listing. The primary listing is argenx · NASDAQ (USD)

€877.60Change from previous close: −0.09%Absolute change: −€0.80

Close · November 16, 2026

Company profile

argenx has 1,863 employees and is headquartered in Amsterdam, Netherlands.

Based in Amsterdam, the Netherlands, argenx SE was incorporated in 2008 and operates as a commercial-stage biopharmaceutical company focused on autoimmune diseases. Its marketed medicines include VYVGART for generalized myasthenia gravis (gMG) and immune thrombocytopenia (ITP), and VYVGART HYTRULO for gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). The pipeline centres on efgartigimod, which is being studied in several other conditions, alongside candidates targeting FcRn, IL-6 and immunoglobulin A. The company sells in the United States, Japan, China and other markets, and has partnerships with Zai Lab, Halozyme Therapeutics, OncoVerity and AbbVie.

In the fiscal year ended December 2025, argenx reported revenue of USD 4.2 billion, up 88.4% from the previous year, and net income of USD 1.3 billion. The United States accounted for 83.2% of revenue, with Japan at 4.9% and China at 1.6%. The company employed 1,863 people. Its shares also trade on NASDAQ.

Company facts

Industry
Biotechnology
Country
Belgium
Headquarters
Laarderhoogtweg 25, 1101 EB, Amsterdam
Employees
1,863
Chief executive
Karen Massey
Founded
2008
Fiscal year
January - December
Listing
ARGX · Euronext Brussels
Currency
EUR
ISIN
NL0010832176
Website
argenx.com

argenx and its competitors

The most similar companies by business and size

CompanyCountryMarket capEmployeesOperating marginP/E (trailing 12 months)
argenxARGXBelgium$61.05B1,86331.9%35.3
BeOne MedicinesONCUnited States$47.58B12,00017.8%53.4
ModernaMRNAUnited States$90.38B4,700-80.8%—
Royalty PharmaRPRXUnited States$39.85B10064.4%45.3
Revolution MedicinesRVMDUnited States$37.27B883-853.0%—
Regeneron PharmaceuticalsREGNUnited States$98.84B15,41030.4%21.1

Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.

Compare argenx with its competitors